Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Marybeth Sechler,1,2 Amber D Cizmic,3 Sreedevi Avasarala,1 Michelle Van Scoyk,1 Christine Brzezinski,1 Nicole Kelley,1 Rama Kamesh Bikkavilli,1 Robert A Winn1–3 1Division of Pulmonary Sciences and Critical Care, 2Program in Cancer Biology, University of Colorado, Aurora, CO, USA; 3Veterans...

Full description

Bibliographic Details
Main Authors:	Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-04-01
Series:	Pharmacogenomics and Personalized Medicine
Online Access:	http://www.dovepress.com/non-small-cell-lung-cancer-molecular-targeted-therapy-and-personalized-a12654

Similar Items

hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression
by: Sreedevi Avasarala, et al.
Published: (2013-05-01)

Heterotrimeric G-protein, Gα16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer.
by: Sreedevi Avasarala, et al.
Published: (2013-01-01)

Personalized medicines – are pharmacists ready for the challenge?
by: Kennedy MJ
Published: (2018-09-01)

KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer
by: Havva O Kilgoz, et al.
Published: (2016-07-01)

Personalized medicine and treatment approaches in non-small-cell lung carcinoma
by: Vadakara J, et al.
Published: (2012-09-01)

Lung cancer drug therapy in Hungary – 3-year experience
by: Moldvay J, et al.
Published: (2015-05-01)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
by: Zago G, et al.
Published: (2016-08-01)

Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy
by: Song X, et al.
Published: (2018-12-01)

Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo
by: Lin QM, et al.
Published: (2019-04-01)

Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
by: Xu ZY, et al.
Published: (2019-07-01)

Chemotherapy for Lung Cancer in the Era of Personalized Medicine
by: Seung Hyeun Lee, M.D., Ph.D.
Published: (2019-04-01)

The methylation profiles of PRDM promoters in non–small cell lung cancer
by: Tan SX, et al.
Published: (2018-05-01)

Potential drug–drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital
by: Tesfaye ZT, et al.
Published: (2017-08-01)

Associations of sirtuins with clinicopathological parameters and prognosis in non–small cell lung cancer
by: Gong J, et al.
Published: (2018-09-01)

The association between Lambert–Eaton myasthenic syndrome and small cell lung carcinoma
by: Briggs SEW, et al.
Published: (2013-05-01)

Personalized Medicine: Pharmacogenomics and Drug Development
by: Somayeh Mirsadeghi, et al.
Published: (2017-03-01)

Pharmacogenomics in Personalized Medicine and Drug Metabolism
by: Wei-Chiao Chang
Published: (2014-01-01)

COPD depicted – patients drawing their lungs
by: Kaptein AA, et al.
Published: (2017-11-01)

Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
by: Wenxiao Jiang, et al.
Published: (2018-07-01)

Polypharmacy and Potential Drug–Drug Interactions in Home-Dwelling Older People – A Cross-Sectional Study
by: Hermann M, et al.
Published: (2021-03-01)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
by: Bylicki O, et al.
Published: (2020-06-01)

Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
by: El-Osta HE, et al.
Published: (2016-08-01)

Predictive Modeling of Drug Treatment in the Area of Personalized Medicine
by: Lesley A. Ogilvie, et al.
Published: (2015-12-01)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
by: Takeda M, et al.
Published: (2019-07-01)

Distinct prognostic values of mRNA expression of glutathione peroxidases in non–small cell lung cancer
by: Liu K, et al.
Published: (2018-08-01)

Borderline personality disorder, trauma, and the hypothalamus–pituitary–adrenal axis
by: Thomas N, et al.
Published: (2019-09-01)

Drug–target–disease network analysis of gene–phenotype connectivity for genistein in ovarian cancer
by: Zhang C, et al.
Published: (2018-12-01)

Novel peptide&ndash;dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer
by: Liping Chu, et al.
Published: (2010-12-01)

Liquid crystalline assembly for potential combinatorial chemo–herbal drug delivery to lung cancer cells
by: Abdelaziz HM, et al.
Published: (2019-01-01)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
by: Seetharamu N, et al.
Published: (2017-07-01)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
by: Mazza V, et al.
Published: (2017-07-01)

Optimising migraine treatment: from drug-drug interactions to personalized medicine
by: Leda Marina Pomes, et al.
Published: (2019-05-01)

Pharmacogenomics of sickle cell disease: steps toward personalized medicine
by: Husain M, et al.
Published: (2017-10-01)

Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer.
by: Meredith A Tennis, et al.
Published: (2012-01-01)

pH-sensitive Au–BSA–DOX–FA nanocomposites for combined CT imaging and targeted drug delivery
by: Huang H, et al.
Published: (2017-04-01)

Editorial: Tissue Engineering for Drug Discovery and Personalized Medicine
by: Qasem Ramadan, et al.
Published: (2021-02-01)

Prediction of Cancer Drug Resistance and Implications for Personalized Medicine.
by: Manfred eVolm, et al.
Published: (2015-12-01)

Growing impact of pharmacogenomic on drug development and personalized medicine
by: Mario Eandi
Published: (2008-01-01)

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
by: Li X, et al.
Published: (2020-01-01)

Structure–activity exploration of a small-molecule Lipid II inhibitor
by: Fletcher S, et al.
Published: (2015-04-01)